KalVista Pharmaceuticals (KALV) Accumulated Expenses (2016 - 2024)
Historic Accumulated Expenses for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $18.9 million.
- KalVista Pharmaceuticals' Accumulated Expenses changed N/A to $18.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.9 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is N/A changed from last year.
- According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Accumulated Expenses is $18.9 million.
- KalVista Pharmaceuticals' Accumulated Expenses' 5-year high stood at $18.9 million during Q4 2024, with a 5-year trough of $4.9 million in Q1 2020.
- Moreover, its 4-year median value for Accumulated Expenses was $9.2 million (2023), whereas its average is $10.0 million.
- Over the last 5 years, KalVista Pharmaceuticals' Accumulated Expenses had its largest YoY gain of 4480.17% in 2020, and its largest YoY loss of 340.0% in 2020.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Accumulated Expenses stood at $6.9 million in 2020, then fell by 23.86% to $5.3 million in 2021, then skyrocketed by 121.51% to $11.7 million in 2023, then skyrocketed by 61.75% to $18.9 million in 2024.
- Its Accumulated Expenses stands at $18.9 million for Q4 2024, versus $15.4 million for Q4 2024 and $10.4 million for Q3 2024.